

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Dumoulin 1



Section 1. Identifying Info							
Identifying Information							
1. Given Name (First Name) Daphne	2. Surname (Last Name) Dumoulin		3. Date 21-October-2020				
4. Are you the corresponding author? Yes No							
5. Manuscript Title Immunotherapy in small cell lung car	ncer: one step at at time. A	narrative review					
6. Manuscript Identifying Number (if you	know it)						
Section 2. The Work Under	Consideration for Publ	ication					
Did you or your institution at any time re	ceive payment or services fror	m a third party (governm	ent, commercial, private foundation, etc.) for				
any aspect of the submitted work (includi statistical analysis, etc.)?	ng but not limited to grants, c	lata monitoring board, s	tudy design, manuscript preparation,				
Are there any relevant conflicts of inte	erest?						
Section 3. Relevant financia	al activities outside the	submitted work.					
	cribed in the instructions. l	Jse one line for each e	cial relationships (regardless of amount ntity; add as many lines as you need by				
Are there any relevant conflicts of inte	·	p	F				
If yes, please fill out the appropriate in	nformation below.						
Name of Entity	Grant	on-Financial Other	Comments				
Roche							
BMS							
MSD							
Pfizer							
Astra Zeneca							
Novartis							

Dumoulin 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Dumoulin reports personal fees from Roche, personal fees from BMS, personal fees from MSD, personal fees from Pfizer, personal fees from Astra Zeneca, personal fees from Novartis, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Dumoulin 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Dingemans 1



Section 1. Identifying Inform	nation			
1. Given Name (First Name) Anne-Marie	2. Surname (Last Name) Dingemans		3. Date 21-October-2020	
4. Are you the corresponding author?	Yes ✓ No	Corresponding A		
5. Manuscript Title Immunotherapy in small cell lung cance	er: one step at at time. A n	arrative review		
6. Manuscript Identifying Number (if you kn	now it)			
		_		
Section 2. The Work Under Co	onsideration for Publi	cation		
Did you or your institution at any time receing any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest.	but not limited to grants, da			:.) for
Section 3. Relevant financial	activities outside the	submitted wor	k.	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	ibed in the instructions. Uport relationships that we lest? Yes No	se one line for ea	ch entity; add as many lines as you need	
Name of Entity	Grant	n-Financial Oth	er? Comments	
Roche			ADVISORY	
BOEHRINGER			ADVISORY	
Pharmamar			ADVISORY	
Pfizer			ADVISORY	
Takeda			ADVISORY	
BMS			Speekers fee	
Lilly			Speekers fee	
Abbyje				

Dingemans 2



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Dingemans 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1. Identifying Inform	ation			
Given Name (First Name) Joachim	Surname (Last Name) Aerts		3. Date 21-October-2020	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Author	r's Name	
5. Manuscript Title Immunotherapy in small cell lung cance	r: one step at at time. A n	arrative review		
6. Manuscript Identifying Number (if you kn	ow it)	_		
Section 2. The West Under Co				
The Work Under Co	onsideration for Public	cation		
Did you or your institution at any time receinany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, da			tc.) for
Section 3. Relevant financial a	activities outside the s	submitted work.		
Place a check in the appropriate boxes in of compensation) with entities as descril clicking the "Add +" box. You should rep Are there any relevant conflicts of intere If yes, please fill out the appropriate info	bed in the instructions. Use ort relationships that were st? Yes No	se one line for each en	tity; add as many lines as you need	d by
Name of Entity	Grant	n-Financial other?	Comments	
msd		✓		
bms				
boehringer ingelheim				
amphera				
eli-lilly				
takeda				
bayer				
roche				



Name of Entity	Grant	? Personal Fees?	Non-Financial Support?	Other?	Comments
astra zeneca		√			
Section 4. Intellectual Do you have any patents, wheth	Property Pa		, ,	ant to the	work? ✓ Yes No
, , ,	riate information	n below. If you	*		ry press the "ADD" button to add a row
Patent?	Pending? Iss	ued? Licenso	ed?Royalties?	License	e? Comments
allogenic tumor cell lysate				amphera	
combination immunotherapy in cancer	✓				
biomarker for immunotherapy	✓				
	ps not covere		perceive to have	influenced	I, or that give the appearance of
potentially influencing, what yo	u wrote in the s	ubmitted wor	k?		
Yes, the following relationsh No other relationships/cond			•	•	
At the time of manuscript accep	-				ary, update their disclosure statement:



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Aerts reports personal fees and non-financial support from msd, personal fees from bms, personal fees from boehringer ingelheim, personal fees from amphera, personal fees from eli-lilly, personal fees from takeda, personal fees from bayer, personal fees from roche, personal fees from astra zeneca, outside the submitted work; In addition, Dr. Aerts has a patent allogenic tumor cell lysate licensed to amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

REMON MASIP 1



Section 1. Identifying Inform	nation			
1. Given Name (First Name) JORDI	2. Surname (Last Name) REMON MASIP		3. Date 21-October-2020	
4. Are you the corresponding author?	Yes ✓ No	Corresponding Au		
5. Manuscript Title Immunotherapy in small cell lung cand	cer: one step at at time. A r	narrative review		
6. Manuscript Identifying Number (if you k	(now it)			
Section 2. The Work Under C	Consideration for Publ	ication		
Did you or your institution at any time reco any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limited to grants, d			etc.) for
Section 3. Relevant financia	l activities outside the	submitted work		
Place a check in the appropriate boxes of compensation) with entities as desc clicking the "Add +" box. You should re Are there any relevant conflicts of intellif yes, please fill out the appropriate in	ribed in the instructions. Leport relationships that we rest?	Jse one line for each	n entity; add as many lines as you ne	ed by
Name of Entity	Grant.	on-Financial Othe	comments	
MSD			ADVISORY	
BOEHRINGER			ADVISORY	
PFIZER			SPEAKER	
OSE IMMUNOTHERAPEUTICS		_	TRAVEL	
BMS			TRAVEL / ADVISORY	
ASTRAZENECA			TRAVEL / ADVISORY	
ROCHE			TRAVEL	

REMON MASIP 2



Section 4.	Intellectual Property Patents & Copyrights
Do you have any	patents, whether planned, pending or issued, broadly relevant to the work? Yes V No
Section 5.	Relationships not covered above
	relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	owing relationships/conditions/circumstances are present (explain below):
✓ No other rela	ationships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. Irnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the ab below.	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
	SIP reports other from MSD, other from BOEHRINGER, other from PFIZER, personal fees and other from OSE PEUTICS, other from BMS, other from ASTRAZENECA, other from ROCHE, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

REMON MASIP 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Section 1. Identifying Inform	nation							
1. Given Name (First Name) Dirk	2. Surnam De Ruysso	-	ne)		3. Date 21-October-2020			
4. Are you the corresponding author?	Yes	✓ No	Correspond Daphne D		or's Name			
5. Manuscript Title Immunotherapy in small cell lung cancer: one step at at time. A narrative review								
6. Manuscript Identifying Number (if you k	now it)							
Section 2. The Week Under C								
The Work Under C	onsiderati	on for P	ublication					
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter	g but not limi	ted to grar				rtc.) 101		
Section 3. Relevant financial	activities	outside 1	the submitted	work.				
Place a check in the appropriate boxes of compensation) with entities as described clicking the "Add +" box. You should read there any relevant conflicts of interesting the sease fill out the appropriate information of the sease fill out the appropriate information.	ribed in the inport relation est?	nstructionships thates	ns. Use one line fo	or each er	ntity; add as many lines as you nee	ed by		
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments			
Boehringer	✓							
Celgene				✓	ADVISORY			
BMS	✓			✓	ADVISORY			
Pfizer				✓	ADVISORY			
Roche				✓	ADVISORY			
Astra Zeneca	✓			✓	ADVISORY			
MSD				✓	ADVISORY			
Seattle genetics				✓	ADVISORY			



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	cther? Comments	
Philips	✓			
Olink	V			
Section 4				
Section 4. Intellectual Propert	ty Patents & Coլ	pyrights		
Do you have any patents, whether plann	ned, pending or issue	ed, broadly relevant	to the work? Yes	✓ No
Section 5. Relationships not o	covered above			
Are there other relationships or activities potentially influencing, what you wrote i			luenced, or that give the	appearance of
Yes, the following relationships/cond				
No other relationships/conditions/cir	rcumstances that pre	esent a potential cor	nflict of interest	
At the time of manuscript acceptance, jo On occasion, journals may ask authors to				disclosure statements.
Section 6. Disclosure Statemen	*			
Disclosure Stateme				
Based on the above disclosures, this forn below.	n will automatically લ્	generate a disclosur	re statement, which will a	appear in the box
Dr. De Ruysscher reports grants from Bo from Roche, grants and other from Astra from Olink, outside the submitted work	a Zeneca, other from			



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Hendriks 1



Section 1. Identifying Inforn	nation			
1. Given Name (First Name) Lizza	2. Surname (Last Name) Hendriks		3. Date 21-October-2020	
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding A		
5. Manuscript Title Immunotherapy in small cell lung canc	er: one step at at time. A n	arrative review		
6. Manuscript Identifying Number (if you k	now it)			
		_		
Section 2. The Work Under C	onsideration for Public	cation		
any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intersection 3. Relevant financial				
Relevant illiancial	activities outside the s	submitted wor	.	
Place a check in the appropriate boxes of compensation) with entities as descr clicking the "Add +" box. You should re	ibed in the instructions. Us	se one line for eac	h entity; add as many lines as you nee	d by
Are there any relevant conflicts of inter-	est? ✓ Yes No			
If yes, please fill out the appropriate inf	ormation below.			
Name of Entity	Grant.	n-Financial upport	er? Comments	
Roche	✓		ADVISORY, speekers fee	
Boehringer	✓		ADVISORY	
AstraZeneca	✓			
BMS			ADVISORY, speekers fee	
Eli Lilly			ADVISORY	
Pfizer			ADVISORY	
Takeda			ADVISORY	7

Hendriks 2

ADVISORY, speekers fee

MSD



Name of Entity	Grant? Personal Fees?	Non-Financial Other	Comments
Section 4. Intellectual Proper	ty Patents & Copy	riahts	
Do you have any patents, whether plant			e work? Yes V No
Section 5. Relationships not	covered above		
Are there other relationships or activitie potentially influencing, what you wrote			ed, or that give the appearance of
Yes, the following relationships/con-			
✓ No other relationships/conditions/ci	rcumstances that pres	ent a potential conflict	of interest
At the time of manuscript acceptance, jo On occasion, journals may ask authors to			essary, update their disclosure statements. relationships.
Section 6. Disalogues Statemen			
Disclosure Stateme	ent		
Based on the above disclosures, this for below.	m will automatically ge	nerate a disclosure sta	ement, which will appear in the box
Dr. Hendriks reports grants and other fr BMS, other from Eli Lilly, other from Pfiz		9	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hendriks 3